191 related articles for article (PubMed ID: 23986189)
1. [Retinal exudative disease in childhood: Coats' disease and familial exudative vitreoretinopathy (FEVR)].
Joussen AM; Gordes RS; Heußen FA; Müller B
Klin Monbl Augenheilkd; 2013 Sep; 230(9):902-13. PubMed ID: 23986189
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
Kodama A; Sugioka K; Kusaka S; Matsumoto C; Shimomura Y
BMC Ophthalmol; 2014 Mar; 14():36. PubMed ID: 24666524
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant anti-VEGF therapy in Coats' disease].
Fiorentzis M; Stavridis E; Seitz B; Viestenz A
Ophthalmologe; 2015 May; 112(5):451-4. PubMed ID: 25134462
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
5. Familial Exudative Vitreoretinopathy: Pathophysiology, Diagnosis, and Management.
Tauqeer Z; Yonekawa Y
Asia Pac J Ophthalmol (Phila); 2018; 7(3):176-182. PubMed ID: 29633588
[TBL] [Abstract][Full Text] [Related]
6. Familial Exudative Vitreoretinopathy.
Sızmaz S; Yonekawa Y; T Trese M
Turk J Ophthalmol; 2015 Aug; 45(4):164-168. PubMed ID: 27800225
[TBL] [Abstract][Full Text] [Related]
7. Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.
Moinuddin O; Sathrasala S; Jayasundera KT; Branham KH; Chang EY; Qian CX; Recchia FM; Fahim AT; Besirli CG
Ophthalmol Retina; 2021 Jan; 5(1):86-96. PubMed ID: 32507488
[TBL] [Abstract][Full Text] [Related]
8. Familial Exudative Vitreoretinopathy With a Novel LRP5 Mutation.
Pefkianaki M; Hasanreisoglu M; Suchy SF; Shields CL
J Pediatr Ophthalmol Strabismus; 2016 Jul; 53():e39-42. PubMed ID: 27486893
[TBL] [Abstract][Full Text] [Related]
9. Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy.
Kashani AH; Brown KT; Chang E; Drenser KA; Capone A; Trese MT
Ophthalmology; 2014 Nov; 121(11):2220-7. PubMed ID: 25005911
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
Lin CJ; Chen SN; Hwang JF; Yang CM
J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization of FZD4, LRP5, and TSPAN12 in Familial Exudative Vitreoretinopathy.
Seo SH; Yu YS; Park SW; Kim JH; Kim HK; Cho SI; Park H; Lee SJ; Seong MW; Park SS; Kim JY
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5143-51. PubMed ID: 26244290
[TBL] [Abstract][Full Text] [Related]
12. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease.
Li S; Deng G; Liu J; Ma Y; Lu H
BMC Ophthalmol; 2017 May; 17(1):76. PubMed ID: 28532448
[TBL] [Abstract][Full Text] [Related]
13. Familial exudative vitreoretinopathy (FEVR) in a child with novel microarray-defined deletion of 11q14 previously diagnosed as retinopathy of prematurity (ROP).
López-Cañizares A; Lazzarini TA; Mendoza C; Berrocal AM
Ophthalmic Genet; 2023 Jun; 44(3):313-317. PubMed ID: 36444989
[TBL] [Abstract][Full Text] [Related]
14. Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.
Yousef YA; ElRimawi AH; Nazzal RM; Qaroot AF; AlAref AH; Mohammad M; Abureesh O; Rejdak R; Nowomiejska K; Avitabile T; Toro MD; AlNawaiseh I
Medicine (Baltimore); 2020 Apr; 99(16):e19623. PubMed ID: 32311932
[TBL] [Abstract][Full Text] [Related]
15. Changing trends in pseudoretinoblastoma diagnoses: A 10 year review from the United Kingdom.
Badhwar V; Yeo DC; Joshi S; Clifton C; Fraser M; Naeem Z; Sagoo MS; Reddy MA
Eur J Ophthalmol; 2023 Jan; 33(1):129-135. PubMed ID: 35484797
[TBL] [Abstract][Full Text] [Related]
16. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center.
Shields CL; Udyaver S; Dalvin LA; Lim LS; Atalay HT; L Khoo CT; Mazloumi M; Shields JA
Indian J Ophthalmol; 2019 Jun; 67(6):772-783. PubMed ID: 31124485
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of peripheral retinal vascular anomalies in family members of patients with familial exudative vitreoretinopathy.
Kashani AH; Learned D; Nudleman E; Drenser KA; Capone A; Trese MT
Ophthalmology; 2014 Jan; 121(1):262-268. PubMed ID: 24084499
[TBL] [Abstract][Full Text] [Related]
18. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats' disease.
Raoof N; Quhill F
Middle East Afr J Ophthalmol; 2013; 20(3):256-8. PubMed ID: 24014992
[TBL] [Abstract][Full Text] [Related]
19. TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT.
Stanga PE; Jaberansari H; Bindra MS; Gil-Martinez M; Biswas S
Retina; 2016 Jan; 36(1):156-62. PubMed ID: 26355946
[TBL] [Abstract][Full Text] [Related]
20. Visual outcomes after treatment in pediatric patients with Coats' disease.
Chiu HH; Wan MJ; Kertes PJ; Muni RH; Lam WC
Can J Ophthalmol; 2019 Dec; 54(6):647-652. PubMed ID: 31836093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
